Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

10395 - Aprocitentan for treating resistant hypertension TS ID 10395 Technology appraisal guidance Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 Technology appraisal ...

Evidence from current practice provided by NHS England and analysed by NICE indicates that digital therapies recommended for PTSD could save over 5,000 hours of therapist time per 1,000 people. Almost ...

Suggested remit: To appraise the clinical and cost effectiveness of Itulazax 12 standardised quality pollen from white birch (betula verrucosa) sublingual lyophilisate immunotherapy (12 SQ-Bet SLIT) ...

A list of downloadable documents created during development.

Rucaparib (Rubraca) is available on the NHS. It is a possible maintenance treatment for relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has ...

There is a simple discount patient access scheme for rucaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by the lead team of committee A, which includes the chair and vice chair. Committee members ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

Rucaparib (Rubraca, Pharm&) is indicated 'as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary ...